Real-time · AI · Cross-signal

Ratio Therapeutics just raised. Here's exactly what to do next.

Who to reach, what to say, and why now — on Ratio Therapeutics, plus every funding round, exec hire, and M&A move that follows. Verified, ICP-ranked contacts on demand (email + mobile).

Used by professionals at BlackRock, Oracle, Kleiner Perkins, HubSpot, and other leading firms — built on 10 years of proprietary signal data.

Choose your plan Request a demo

Everyone else gives you a piece

✕Crunchbase & PitchBook list the company — No person, no timing, no opener.

✕ZoomInfo & Apollo sell you a contact — No trigger, no reason to reach out now.

✕LinkedIn Sales Navigator shows you people — No real-time signal, no opener.

✕Clay enriches lists you built — No live signal of its own, no who or when.

✕ChatGPT & gen-AI tools answer on a delay — No live data, no verified contact.

Who to contactWhat to sayWhen to reach outWhy now

Only Fundz delivers all four.

Ratio Therapeutics Announces $50M Series B Financing to Advance Targeted Radiotherapies for Cancer Treatment

PRIVATEJan 17, 2024•over 2 years ago

Amount Raised

$50 Million

BostonBiotechnology

Investors

Center For Technology Licensing At Cornell UniversityBristol Myers SquibbPags GroupDuquesne

Description

Ratio Therapeutics Inc. announces the close of its $50M Series B financing, bringing the total raised to date to over $90 million, with continued participation from Series A leads and new investors PagsGroup, Bristol Myers Squibb, and the Center for Technology Licensing at Cornell University.

Company Information

Company

Ratio Therapeutics

Location

Boston, Massachusetts, United States

About

Ratio Therapeutics Inc. is a clinical-stage pharmaceutical company with the mission to accelerate the development of next-generation precision radiopharmaceuticals for solid tumors and transform oncology treatment paradigms. With headquarters and laboratories in Boston, the company currently employs a growing team of multidisciplinary experts with backgrounds in radiopharmaceutical discovery and development. Ratio's proprietary R&D platforms, Trillium™ and Macropa™, enable the development of fit-for-purpose radiopharmaceuticals for therapy and imaging that possess pharmacokinetic modulation, thereby improving drug availability, tumor delivery, and tumor loading. The company maintains a strong commitment to manufacturing through its collaboration with PharmaLogic and its own state-of-the-art facility located in Salt Lake City, Utah, ensuring reliable supply and quality in radiopharmaceutical production. Ratio plans to initiate a Phase 1/2 trial to evaluate the safety, tolerability and efficacy of its FAP-targeted radiotherapeutic as a treatment for patients with relapsed or refractory soft tissue sarcoma. The company is also advancing other programs in its pipeline, including the pre-clinical assessment of [Lu-177]-RTX2358 across several cancer indications to explore its broader therapeutic potential and expects its Granzyme B-targeted agent for PET imaging program to move into the clinic in 2026.

Related People

Suggested for you

1 contact

Choose your plan to reveal verified contacts

Predictive Intelligence

Strategic

ML-powered predictions for Ratio Therapeutics's next move

Learn about Strategic plan

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Watching Ratio Therapeutics? See every signal — funding, hires, M&A, contracts, sentiment.

Request a demo Choose your plan